Metacrine Inc. (fka MTCR)

[DewDiligence]

MTCR -50%/AH on discontinuation of FXR/NASH program:

https://www.globenewswire.com/news-release/2021/10/21/2318743/0/en/Metacrine-Reports-Interim-Results-for-MET642-Phase-2a-Trial-in-Patients-with-NASH-and-Announces-a-Strategic-Re-Prioritization-of-Its-Clinical-Development-Programs.html

“After a rigorous assessment of our NASH and IBD programs, including the significant capital and resources required to progress these large clinical development programs, we have made the decision to focus Metacrine’s clinical development effort and financial resources on moving MET642 into a Phase 2 trial in IBD in the first half of 2022 and to halt future development of the FXR program in NASH. This decision was influenced in part by a potential delay in confirming appropriate safety margins in our long-term toxicology work that would impact the timing of future NASH studies, but is unlikely to impact timelines for the IBD clinical program.”

That was in the seventh paragraph of the PR, LOL.